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Abstract Marine oils rich inω-3 polyunsaturated fatty
acids have been recommended as a preventive treatment
for patients at risk for cardiovascular diseases. These
oils also are the third most consumed dietary supple-
ment in the USA. However, evidence for their health
benefits is equivocal. We tested the daily, isocaloric
administration of krill oil (1.17 g oil/kg diet) and
Lovaza (Omacor; 4.40 g/kg diet), a pharmaceutical
grade fish oil, beginning at 12 months of age, on the
life span andmortality-related pathologies of long-lived,
male, B6C3F1 mice. The oils were incorporated into the
chemically defined American Institute of Nutrition
(AIN)-93 M diet. An equivalent volume of soybean oil
was removed. Krill oil was 3 % and Lovaza 11 % of the
oil in the diets. When their effects were analyzed togeth-
er, the marine oils significantly shortened life span by
6.6 % (P=0.0321; log-rank test) relative to controls.
Individually, Lovaza and krill oil non-significantly
shortened median life span by 9.8 and 4.7 %, respec-
tively. Lovaza increased the number of enlarged seminal
vesicles (7.1-fold). Lovaza and krill oil significantly
increased lung tumors (4.1- and 8.2-fold) and hemor-
rhagic diathesis (3.9- and 3.1-fold). Analysis of serum
from treated mice found that Lovaza slightly increased
blood urea nitrogen, while krill oil modestly increased
bilirubin, triglycerides, and blood glucose levels. Taken
together, the results do not support the idea that the
consumption of isolated ω-3 fatty acid-rich oils will
increase the life span or health of initially healthy
individuals.
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Introduction
Isolated marine oils such as fish oil and krill oil are the
third most popular dietary supplement in the USA
(Hersher 2012). They are thought to produce positive
health outcomes because they contain high concentra-
tions of two major n-3-long-chain, polyunsaturated fatty
acids (PUFAs; ω-3 fatty acids): eicosapentaenoic acid
(EPA; 20:5n-3) and docosahexaenoic acid (DHA;
22:6n-3) (reviewed in Kar 2011; Rizos et al. 2012).
Elevated dietary intakes of EPA and DHA can reduce
hyperlipidemia in mice (Ruzickova et al. 2004), rats
(Rustan et al. 1992), and humans (Mozaffarian and
Wu 2012). Marine oils may reduce triglyceride levels,
arrhythmias, platelet aggregation, and blood pressure
(reviewed in Kar 2011; Rizos et al. 2012). One recent
meta-analysis suggested that the consumption of fish
and marine n-3 polyunsaturated fatty acids may reduce
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the risk of breast cancer (Zheng et al. 2013), while
another meta-analysis found no change in overall mor-
tality with omega-3 fatty acid consumption (Zhang et al.
2014). In 2004, a concentrated and highly purified fish
oil, trade named Lovaza in the USA and Omacor in
Europe (Kar 2011), was approved as a drug by the US
Food and Drug Administration for the treatment of
hyperlipidemia. A number of European regulatory agen-
cies also approved the use of marine PUFAs for reduc-
ing cardiovascular risk factors (Rizos et al. 2012).
Despite these approvals and the positive effects on
some cardiovascular risk factors, randomized clinical
trials have found mixed results regarding the benefits
of marine PUFAs for the prevention of adverse cardio-
vascular events (Marchioli et al. 2002; Yokoyama et al.
2007; Tavazzi et al. 2008; Kromhout et al. 2010;
ORIGIN Trial Investigators et al. 2012). A recent
meta-analysis of 20 studies and 68,680 patients found
no association of PUFA supplementation with lower
risk of all-cause mortality, cardiac death, sudden death,
myocardial infarction, or stroke based on relative or
absolute measures of association (Rizos et al. 2012).
Consistent with these results, another meta-analysis
found insufficient evidence for a secondary preventive
effect of ω-3 fatty acid supplements against overall
cardiovascular events among patients with a history of
cardiovascular disease (Kwak et al. 2012).
The consumption of dietary marine oils may have
adverse consequences. A fish oil-containing diet ap-
pears to reduce immune responsiveness to
Helicobacter hepaticus infection, exacerbating a mouse
model of inflammatory colitis and increasing colon
cancer risk (Woodworth et al. 2010). Increased serum
aspartate aminotransferase and alanine aminotransferase
activity, which can be evidence of liver toxicity, are
adverse reactions reported in clinical studies of Lovaza
(GlaxoSmithKline 2013). Hemorrhagic diathesis also is
a postmarketing adverse reaction observed with Lovaza
(GlaxoSmithKline 2013). Evidence of increased pros-
tate cancer risk among men with high blood concentra-
tions of long-chain ω-3 PUFAs was reported recently
(Bassett et al. 2013; Brasky et al. 2013).
Because of the complex and somewhat paradoxical
nature of the results summarized above, we investigated
the effects of both Lovaza and food grade krill oil on life
span and mortality-related pathology, two key health-
related outcomes. We utilized long-lived, male F1 hy-
brid mice supplemented with krill oil or Lovaza begin-
ning at 12 months of age. The effects of the compounds
on food consumption, body weight, and mortality-
associated outcomes were determined throughout the
study period.
Results
Life span Male C3B6F1 mice were supplemented be-
ginning at 12 months of age with food containing krill
oil or Lovaza. The dosages given and the rationale for
them are discussed below. When the effects of the
marine oils on longevity were analyzed together using
the Mantel–Cox log-rank test, they significantly de-
creased life span by 6.6 % (P=0.0321). Individually,
Lovaza and krill oil non-significantly shortened mean
life span by approximately 9.8 and 4.7 %, respectively
(Fig. 1). These data probably were not significant indi-
vidually because of sample size.
These studies were a part of a larger study in which
one control group of 297mice and 58 treatment groups of
36 mice each were used to screen for the effects of
different compounds on life span (e.g., Spindler et al.
2013a, b). Other of these treatments increased life span,
although most had no effect. For example, treatment of
the mice with β-adrenergic receptor blockers or 40 %
caloric restriction (CR) produced a significant 8.4 and
23 % increase in life span (Spindler et al. 2013b). In
contrast, other compounds produced no effect on life
Fig. 1 Life span of mice fed a control diet or a diet supplemented
with Lovaza or krill oil. Shown are the life spans of the control
(filled circles), krill oil-treated mice (downward-pointing trian-
gles), and Lovaza-treated mice (upward-pointing triangles). The
percentage of mice remaining alive at the end of each time period
shown is plotted. The controls began with 297 mice and the
treatment groups with 36 mice each. The graph begins at 365 days
of age, when treatments were started
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span (e.g., Spindler et al. 2013a, 2014). The sample sizes
in this study are similar to those required for a Weibull
survival analyses with a 75 % probability of detecting
a 10 % increase in mean life span with a 1 % (β≤0.01)
probability of a false positive. The Weibull survival
analysis is more stringent than the log-rank test
(Jeske et al. 2014).
Rationale for dosages Krill oil was administered at
1.17 g oil/kg diet, which is ~124 mg/kg body weight
per day (mg/kg bw/day), or approximately 3 % of the oil
in the diet. The calculation assumes a body weight of
39 g, which is approximately the median weight of the
mice during the treatments (Fig. 2). Lovaza was admin-
istered at 4.40 g/kg diet, which is ~467 mg/kg bw/day, or
approximately 11 % of the oil in the diet. An equivalent
volume of soybean oil was removed from each diet to
compensate calorically for the additions. The American
Institute of Nutrition (AIN)-93 M diet contains 40 g
soybean oil per kg diet, which provides only small
amounts of EPA or DHA from the inefficient metabolic
conversion of other fatty acids in the oil (Reeves et al.
1993; De Caterina 2011). The krill oil brand used is 23%
EPA and 6.5 % DHA by weight, while Lovaza is 55 %
EPA and 45 % DHA by weight. We could not find a
literature describing the use of Lovaza in mice. The
recommended dose in humans is 4.0 g/day, which would
provide 50 mg/kg bw/day for an 80-kg adult. The cross-
species scaling factors used to adjust dosages between
animals and humans suggest that mice should receive 8
to 12 times the effective human dosage of a drug to
account for species-specific pharmacodynamic and phar-
macokinetic differences (reviewed in Spindler 2012).
The Lovaza dose used here is approximately 9.3 times
the recommended human dosage per kilogram body
weight. The krill oil dosage is modest in comparison to
the dosages used in mouse studies to demonstrate a
beneficial effect on serum and hepatic cholesterol and
triglyceride levels (Vigerust et al. 2012; Tandy et al.
2009). For example, tumor necrosis factor alpha-
transgenic mice fed a high-fat diet containing 5.8 % krill
oil (approximately five times the dosage used here) had
lower plasma levels of triacylglycerol and cholesterol and
higher levels of hepatic mitochondrial and peroxisomal
fatty acid β-oxidation and carnitine turnover (Vigerust
et al. 2012). High fat-fed mice receiving krill oil at
12.5 g/kg diet (approximately 10 times that used here)
had reduced hepatomegaly, hepatic steatosis, triacylglyc-
erols, and cholesterol (Tandy et al. 2009).
Food consumption and body weight To determine the
possible effects of the compounds on food intake and
body weight, the mice were fed a known number of
calories each day, and both parameters were quantified
throughout the study (Fig. 2). As is typical of meal-fed
B6C3F1 mice, all the mice began to lose weight begin-
ning at about 12 months of age, even though they were
eating near ad libitum levels of calories (e.g., Spindler
et al. 2013a, b; Martin-Montalvo et al. 2013). As in our
previous studies, the mean weight estimates became
increasingly unstable as days on diet increased, because
the number of mice diminished with time (Spindler et al.
2013a, b). Thus, neither the Lovaza nor the krill oil diet
produced a consistent treatment effect on body weight
(Fig. 2). Anomalously, at 1,125 days of age, the Lovaza
diet-fed mice consumed only 78 % of the food offered
(Fig. 2). However, only five of the mice remained at this
time. Three of these mice died in the ensuingmonth, and
the remaining mice consumed a more “normal” amount
of food.
Necropsies Necropsy results are shown in Tables 1 and 2.
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Fig. 2 Body weights and food consumption of the mice. The
symbols are as labeled in the figure. The notation Percent of Kcal
consumed refers to the percent of the food eaten with respect to the
amount presented to the mice in each treatment group per mouse
during the preceding 30 days with respect to the amount consumed
by the control mice during the same period. For the weights of the
mice, the median weight plus or minus the standard deviation is
shown. The differences between the weights of the groups were
not significant, as judged using a linear mixed effects model as
described previously (Spindler et al. 2013a)
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age at death to approximate the age distribution of the
entire cohort. Both Lovaza and krill oil consumption
significantly increased the number of mice with peritoneal
hemorrhagic diathesis (bleeding into the peritoneum;
Table 1). The increase was 3.9-fold for Lovaza and 3.1-
fold for krill oil. As mentioned in the “Introduction,”
hemorrhagic diathesis is a postmarketing adverse reaction
which has been reported for Lovaza by GlaxoSmithKline
(2013). We were unable to determine the frequency or
severity of this outcome from the information available.
In our study, Lovaza treatment also produced a signifi-
cant increase in the number of enlarged seminal vesicles
(7.1-fold; Table 1). There was a 52 % reduction in the
median liver tumor mass in the Lovaza-treated mice
(Table 2). This size reduction may not have been the
result of their shortened life spans, since a similar effect
was not found for the krill oil-treated mice (e.g., Dhahbi
et al. 2004; Spindler 2005). Lovaza and krill oil treat-
ment produced a significant 4.1- and 8.2-fold increase,
respectively, in the number of lung tumors (Table 1).
Thus, marine oil consumption was associated with an
increase in the onset, incidence, or severity of multiple
adverse health outcomes.
Serum tests To determine whether the decrease in life
span was related to drug-induced toxicity, serum sam-
ples were analyzed frommice of the same sex and strain
fed the Lovaza or krill oil diets (Tables 3 and 4). Most of
the parameters measured were not changed significantly
by the treatments, suggesting that the oils were not
overtly toxic to the liver, muscle, kidney, or other
organ systems. Lovaza produced a modest reduction
in blood urea nitrogen (Table 3). However, this change
was quantitatively modest, not found in the krill oil
diet-treated group, and is therefore of uncertain signif-
icance. The Lovaza-treated mice did have unkempt hair
coats, which can be a symptom of generalized illness.
The krill oil-treated group showed limited signs of
toxicity. Their bilirubin, triglyceride, and glucose levels
were modestly elevated (Table 4). Elevation of these
Table 1 Necropsy results from the mouse longevity studies shown in Fig. 1
Organ Pathology Diet treatment (n)
Control (n=36)a Lovaza (n=35) Krill oil (n=35)
No.b %c No. % P valued No. % P value
Spleen Enlarged/tumorous 23 63.9 23 65.7 1.0000 20 57.1 0.6312
Liver Tumor 11 30.6 17 48.6 0.1488 13 37.1 0.6210
Enlarged/fatty liver 1 2.8 1 2.9 1.0000 3 8.6 0.3570
Hemangioma 4 11.1 1 2.9 0.3570 0 0.0 0.1145
Intestinal Tumor 5 13.9 8 22.9 0.3723 4 11.4 1.0000
Lung Tumor 2 5.6 8 22.9 0.0457 16 45.7 9.769e-05
Penis Necrosed/inflamed 0 0 2 5.7 0.2394 0 0.0 1.0000
Seminal vesicles Enlarged 1 2.8 7 20.0 0.0278 3 8.6 0.3570
Bladder Distended 6 16.7 5 14.3 1.0000 2 5.7 0.2603
Kidneys Enlarged/tumorous 3 8.3 0 0.0 0.2394 2 5.7 1.0000
Thymus Enlarged 1 2.8 3 8.6 0.3570 4 11.4 0.1987
Skin/abdominal cavity Fibroma 1 2.8 1 2.9 1.0000 2 5.7 0.6142
Peritoneal cavity Hemorrhage 4 11.1 15 42.9 0.0032 12 34.3 0.0246
a Number of necropsied mice in each treatment group. The necropsied control mice were chosen randomly from among the mice of
appropriate ages for approximating the age distribution of the marine oil-treated mice. One mouse from each treatment group was
cannibalized and could not be necropsied
bNumber of necropsied mice in each treatment group with the indicated pathologies
c Percent of the necropsied mice in the treatment group with the indicated pathologies
d Fisher’s exact test was utilized to investigate the association between the pathologies and treatment groups. The values that were
significantly different or near significance are in italics. The P values are two-sided
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parameters can be a sign of liver dysfunction. The Lovaza-
treated mice also had numerically elevated triglycerides,
although this change did not reach significance. High fat-
fedmice receiving krill oil at 12.5 g/kg diet (approximately
10 times that used here) had reduced triacylglycerol and
cholesterol levels (Tandy et al. 2009). However, we found
an opposite effect on triglycerides for mice consuming the
AIN-recommended levels of fat and carbohydrate
(AIN-93 M diet; Table 3) (Reeves et al. 1993).
Discussion
The work presented here shows for the first time that the
consumption of either commercial or pharmaceutical
grade marine oils can have adverse health effects. The
krill oil dosage we used is below that commonly used
for the treatment of mice in the scientific literature. In
the case of Lovaza, the recommended human dose was
scaled up according to accepted cross-species scaling
factors. Both oils were present as a relatively small
fraction of the total oil in the diet.
Of the pathologies found upon necropsy, hemorrhagic
diathesis seems likely to be responsible for a significant
proportion of the early mortality of the treated mice. It
was substantially and significantly elevated in both the
Lovaza- and krill oil-treated mice (Table 1). It is a prob-
able consequence of the anticoagulant effects of dietary
marine oils observed in both rodents and humans (Calder
and Yaqoob 2012; Sano et al. 2003). The increase in lung
tumors in the Lovaza- and krill oil-treated mice also may
have contributed to their early mortality. Recent evidence
suggests that a diet containing fish oil promotes tumor
growth by suppressing CD8+ activation inmice (Xia et al.
2014). Thus, the anti-inflammatory effects of marine oils
may have negative as well as positive consequences. A
fish oil-containing diet significantly decreased the num-
ber of CD8+ T cells in the lungs of influenza virus-
infected mice, leading to elevated rates of morbidity and
mortality (Schwerbrock et al. 2009).
Serum tests found little evidence for a significant level
of toxicity related to marine oil consumption. The in-
crease in total bilirubin, triglycerides, and glucose in the
krill oil-treated group and blood urea nitrogen in the
Lovaza-treated mice is modest and not likely sources of
early mortality. Thus, there is little evidence that the
detrimental effects of these PUFAs on survival are the
result of direct toxic effects of the oils or contamination of
Table 2 Liver tumor mass of the




Control (n=36) Lovaza (n=35) Krill oil (n=35)
Mass (g)a Mass (g) Mass (g)
Median mass of each tumor 0.54 0.28 (P=0.033)b 0.61 (P=0.231)
Tumor mass/number of mice with tumors 1.1 1.1 1.3
Table 3 Serum tests for Lovaza
diet-fed mice. Six treated and six
control 19-month-old mice of the
same sex and strain used in the life
span studies were fed the Lovaza
supplemented diet for 16 weeks
prior to bleeding by heart puncture
aBlood glucose levels were mea-
sured with the FreeStyle Lite
Blood Glucose Monitoring Sys-
tem (Abbot Laboratories). The
other blood tests were performed
by the Comparative Pathology
Laboratory, University of
California, Davis
bCalculated using two-sample t tests
Testa Control Lovaza P valueb
Alanine aminotransferase (U/L) 30.3±11.9 28.1±7.5 0.720
Aspartate aminotransferase (U/L) 157.9±36.3 112.4±44.3 0.083
Alkaline phosphatase (U/L) 60.0±10.3 56.3±14.3 0.624
Blood urea nitrogen (mg/dL) 19.1±3.1 14.5±2.7 0.021
Cholesterol (mg/dL) 182.5±21.1 163.9±31.5 0.263
Creatinine (mg/dL) 0.069±0.012 0.076±0.023 0.535
High-density lipoprotein (mg/dL) 196.4±27.3 173.0±34.8 0.229
Low-density lipoprotein (mg/dL) 19.17±3.86 16.74±5.98 0.428
Total bilirubin (mg/dL) 0.093±0.025 0.123±0.045 0.188
Total protein (g/dL) 6.27±0.38 5.94±0.50 0.234
Triglyceride (mg/dL) 69.5±37.0 112.1±99.2 0.362
Glucose, non-fasting (mg/dL) 176.3±24.1 151.3±26.2 0.120
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the oils by the environmental pollutants commonly asso-
ciated with marine fish, such as methyl mercury, dioxins,
or polychlorinated biphenyls (Turunen et al. 2010).
Lovaza is a highly purified prescription drug, with very
low levels of these toxicants (GlaxoSmithKline 2013).
It is unlikely that the negative effects of these diets on
life span were related to the presence of high levels of
oxidation products in the oils themselves. The oils were
supplied in sealed capsules. These were rapidly opened,
combined, and stored sealed in bottles under argon. The
bottles were sent to BioServ via expedited shipping. At
BioServ, the oils were opened and compounded with the
diets, cold pressed into food pellets, and packed in airtight
plastic bags. After receipt in the laboratory, the plastic
bags of food were stored at −20 °C. Approximately
1-week aliquot of food was transferred from these bags
into airtight Rubbermaid tubs, which were stored at
−20 °C. The plastic tubs were warmed to room tempera-
ture each day before opening for feeding and then returned
to the freezer.
As discussed in the “Introduction,” the evidence for an
association between marine oil consumption and better
health or survival is equivocal. To the best of our knowl-
edge, there are no long-term human or mouse survival
studies performed with either Lovaza or other marine oils
using initially healthy subjects. A study with senescence-
accelerated mice found that the long-term oral adminis-
tration of fish oil decreased life span (Tsuduki et al. 2011).
While these results are similar to ours, studies performed
in enfeebled mouse models have a limited predictive
value for outcomes in healthy subjects (Spindler 2012).
For example, among the many compounds reported to
extend the life span of enfeebled mice, only one has
been shown to extend the life span of healthy mice
(Martin-Montalvo et al. 2013; Anisimov et al. 2005a, b).
F1 hybrid mice were utilized for these studies be-
cause they are heterozygous for the alleles differing
between their parents. They tend to be more robust
and longer lived than their inbred parental lines
(Spindler and Mote 2007; Spindler 2012). We have
shown that their life span is responsive to multiple
interventions including CR (Spindler et al. 2013a), β1-
adrenergic receptor antagonists (Spindler et al. 2013b),
and metformin (Martin-Montalvo et al. 2013), suggest-
ing that they are appropriate models for testing potential
longevity therapeutics.
Conclusions
Doses of krill oil and Lovaza consistent with those
recommended for human use decreased the life span of
healthy mice. Marine oil consumption increased deaths
associated with hemorrhagic diathesis and specific tu-
mor types. In light of the current uncertainties regarding
the efficacy of purified marine oils in treating human
diseases, our results do not support their use to increase
health or life span.
Materials and methods
Mouse husbandry and life span studies The study de-
sign and husbandry conditions are described in detail
Table 4 Serum tests for krill oil
diet-fed mice. Six treated and six
control 16-month-old mice of the
same sex and strain used in the life
span studies were fed the krill oil
supplemented diet for 11 weeks
prior to bleeding by heart puncture
aBlood glucose levels were mea-
sured with the FreeStyle Lite
Blood Glucose Monitoring Sys-
tem (Abbot Laboratories). The
other blood tests were performed
by the Comparative Pathology
Laboratory, University of Cali-
fornia, Davis
bCalculated using two-sample t tests
Testa Control Krill oil P valueb
Alanine aminotransferase (U/L) 45.6±29.8 29.3±7.7 0.251
Aspartate aminotransferase (U/L) 106.8±31.2 110.7±17.7 0.798
Alkaline phosphatase (U/L) 73.1±15.2 72.9±9.1 0.982
Blood urea nitrogen (mg/dL) 18.7±2.4 19.9±2.4 0.408
Cholesterol (mg/dL) 186.4±43.4 187.7±34.7 0.957
Creatinine (mg/dL) 0.052±0.017 0.055±0.017 0.817
High-density lipoprotein (mg/dL) 175.9±39.4 179.8±34.4 0.860
Low-density lipoprotein (mg/dL) 28.1±14.0 27.8±10.9 0.963
Total bilirubin (mg/dL) 0.081±0.011 0.115±0.029 0.034
Total protein (g/dL) 6.40±0.63 6.44±0.73 0.921
Triglyceride (mg/dL) 72.0±14.8 95.9±14.8 0.021
Glucose, non-fasting (mg/dL) 111.3±33.9 158.0±23.5 0.024
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elsewhere (Spindler et al. 2013a, b). Briefly, male
B6C3F1 mice (Harlan Breeders; Indianapolis) were ran-
domly assigned to treatment groups at 12 months of age
and switched to daily feeding with 13.3 kcal/day/mouse
of control diet (AIN-93 M, Diet No. F05312; BioServ,
Frenchtown, NJ). The control group was composed of
297 mice. Test cohorts of 36 mice were fed control diet
supplemented with either krill oil (Neptune Krill Oil,
Jarrow) or Lovaza (GlaxoSmithKline) at the dosages
indicated in the text. Fifty-six other groups of mice were
fed other chemical agents in their diets or were calori-
cally restricted. All mice were fed daily. Food consump-
tion was monitored at the time of feeding, and any
uneaten food was noted. Dead mice were stored at
−20 °C until necropsy. Kaplan–Meier survival curves
were compared using the log-rank test implemented in
GraphPad Prism 5.01. The probability of detecting a false
positive or negative was less than 1 % (Jeske et al. 2014).
The statistics were not corrected for multiple testing. The
data were not censored. Mice were weighed bimonthly,
and the weights recorded. The significance of the differ-
ences in weight was determined as described previously
(Spindler et al. 2013a). Because the mice were multiply
caged, food consumption was determined by totaling the
amount eaten by each treatment group during each time
period, adjusted for the number ofmice in each cage. This
number was divided by the amount eaten by the control
mice, also adjusted for the number of mice alive per cage.
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